Clare Hall Member contributes to groundbreaking research on early treatment for Crohn’s disease
Dr Nurulamin Noor, Affiliated Postdoctoral Member of Clare Hall, has contributed to major new research from the University of Cambridge demonstrating that early treatment for Crohn’s disease leads to better patient outcomes and could save millions for healthcare systems worldwide.
The findings build on the landmark PROFILE trial, led by researchers at the School of Clinical Medicine, University of Cambridge, and published in The Lancet Gastroenterology & Hepatology in 2024. The trial showed that very early use of treatment in patients newly diagnosed with Crohn’s disease was highly effective and safer than traditional approaches.
A new health economic analysis, published in the Journal of Crohn’s and Colitis last week, complements those results by showing that early intervention is also cost-effective, reducing long-term healthcare costs and improving access to timely care. The study suggests that this approach can help reduce inequalities in treatment for patients living with inflammatory bowel disease globally. The research was carried out by a collaborative team from Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge.
The work has attracted international attention, featuring in BBC News and scientific media worldwide. It represents a significant advance in the management of Crohn’s disease, supporting earlier diagnosis and treatment to improve patient outcomes and reduce the burden on health services.
In further recognition of its impact, the PROFILE project has been shortlisted for the Times Higher Education National STEM Research Project of the Year Award. Winners will be announced on Thursday 13 November, at the annual awards ceremony in Edinburgh.
Read more: